CatalystBio

Executive Summary

CatalystBio is a biotech advisory firm providing end-to-end consulting and fractional leadership to accelerate product development. Founded in 2017 and based in South San Francisco, the company helps early-stage biotechs reach critical value inflection points—such as IND filings and clinical trial initiations—by offering strategic direction and operational execution. Despite being pre-clinical, CatalystBio focuses on de-risking and streamlining the path to clinic for its clients, particularly in hematology and antibody therapeutics. Its service-based model generates revenue without the capital intensity of drug development, positioning it as a resilient partner in the biotech ecosystem. As the industry faces increasing pressure to improve R&D efficiency, CatalystBio's model of providing just-in-time expertise is well-timed to capture demand from resource-constrained startups and established firms seeking to optimize their pipelines.

Upcoming Catalysts (preview)

• Q3 2026Landing a marquee client for a major antibody program40% success
• Q4 2026Expansion of service offerings into gene therapy or cell therapy advisory30% success
• Q4 2026Formation of a strategic partnership with a CRO or CDMO to provide integrated services35% success